Mortality
no changein humans1upin humans1
Myasthenia gravis has no effect on mortality in humans.
“After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).”
Humansadjusted for time-varying Charlson Comorbidity Index
Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia Gravis
Muscle & nerve17 Oct 2025
Myasthenia gravis increases mortality in humans (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).
“The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).”
Humansunadjusted
Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia Gravis
Muscle & nerve17 Oct 2025
Infection-specific mortality
upin humans1
Myasthenia gravis increases infection-specific mortality in humans (2.0 vs. 1.2 per 1000-person-year, p < 0.01).
“mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2)”
Humans
Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia Gravis
Muscle & nerve17 Oct 2025
Age at death
upin humans1
Myasthenia gravis is associated with age at death in humans (+4.8 years versus the general population).
“MG patients showed a higher mean age at time of death compared with the general population (+4.8 years, p < 0.0001)”
HumansCompared with the general U.S. population under historical standard-of-care conditions2000, 2005, 2010, and 2015
Therapeutic advances in neurological disorders1 Aug 2026
Mitochondrial DNA copy number
upin silico1OR 1.592
Mitochondrial DNA copy number raises the risk of myasthenia gravis in silico (OR = 1.592, 95% CI 1.025-2.473, P = 0.039).
“mtDNA-CN were associated with MG (OR = 0.909, 95% CI 0.834-0.991, P = 0.030; OR = 1.592, 95% CI 1.025-2.473, P = 0.039)”
In silicogenetically predicted
Clinical epigenetics14 Feb 2026
HannumAge
downin silico1OR 0.909
HannumAge lowers the risk of myasthenia gravis in silico (OR = 0.909, 95% CI 0.834-0.991, P = 0.030).
“Overall, genetically predicted HannumAge and mtDNA-CN were associated with MG (OR = 0.909, 95% CI 0.834-0.991, P = 0.030”
In silicogenetically predicted
Clinical epigenetics14 Feb 2026
Company3 trialsPhase 3174 people
Company1 trialPhase 2/366 people
Company1 trialPhase 152 people
Company1 trialPhase 130 people
First Affiliated Hospital of Wenzhou Medical University
1 trialPhase 430 people
University of Alabama at Birmingham
1 trialPhase 3126 people
University of Kansas Medical Center
1 trialPhase 250 people
1 trialPhase 19 people
Medicare beneficiaries with the disease had 8% higher mortality risk at 12 months than those without myasthenia gravis.Medicare beneficiaries with the disease had 8% higher mortality risk at 12 months than those without myasthenia gravis.